The probiotics company Probi, which is being acquired, is applying for delisting of its shares from Nasdaq Stockholm.

The bidder Symrise controls more than 90 percent of the shares in Probi and has communicated that it intends to call for compulsory acquisition of the remaining shares in the company.

The Board of Directors of Probi has decided to convene an Extraordinary General Meeting to be held on February 13 this year for, among other things, the election of new Board members.